<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00925392</url>
  </required_header>
  <id_info>
    <org_study_id>DORICPK4002</org_study_id>
    <nct_id>NCT00925392</nct_id>
  </id_info>
  <brief_title>Doripenem Intrapulmonary Pharmacokinetics in Healthy Adult Subjects</brief_title>
  <official_title>Doripenem Intrapulmonary Pharmacokinetics in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Keith A. Rodvold</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pulmonary Associates, PA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Illinois at Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being performed to measure the amount of the antibiotic doripenem (study drug)
      found in the fluid and cells of the lung and blood after receiving three doses of doripenem.
      The major objectives of this research are to see how much and for how long doripenem gets
      into the fluids and cells of the lungs of healthy adult subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this descriptive study is to determine and compare the plasma,
      epithelial lining fluid (ELF), and alveolar macrophages (AM) concentrations following
      multiple intravenous doses of doripenem in healthy, non-smoking adult subjects. In brief,
      each subject who qualifies for the study will be randomized to one of two dosing regimens:
      doripenem 500 mg or doripenem 1000 mg every 8 hours for a total of three intravenous doses.
      Each dose of doripenem will be administered as an intravenous infusion over 4 hours. Serial
      blood samples for determining plasma doripenem concentrations will be collected prior to and
      after the start of the intravenous infusion of the third doripenem dose. Each subject will
      undergo one standardized bronchoscopy with BAL in the outpatient bronchoscopy suite at one of
      four sampling times after the start of the intravenous infusion of the third doripenem dose.
      BAL collection will provide samples to determine drug concentration in ELF and AM. Safety
      will be assessed throughout the study by adverse event monitoring, clinical laboratory tests,
      and vital sign monitoring.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective is to determine and compare the plasma, epithelial lining fluid, and alveolar macrophages concentrations following multiple intravenous doses of doripenem in healthy, non-smoking adult subjects.</measure>
    <time_frame>32 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary objective of this study is the assessment of safety and tolerability of doripenem as measured by the overall incidence of treatment-emergent adverse events.</measure>
    <time_frame>24 hours post end of doripenem administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Doripenem 500 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Doripenem 1000 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doripenem</intervention_name>
    <description>Intravenous 500 mg every (q) 8 hours for 3 doses</description>
    <arm_group_label>Doripenem 500 mg</arm_group_label>
    <other_name>Doribax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doripenem</intervention_name>
    <description>Intravenous 1000 mg q 8 hours for 3 doses</description>
    <arm_group_label>Doripenem 1000 mg</arm_group_label>
    <other_name>Doribax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy men and women at least 18 years of age who have no history of smoking within
             the last 1 year.

          -  Subjects must be healthy with no clinically important abnormalities in the medical
             history, physical examination, or laboratory values.

        Exclusion Criteria:

          -  Subjects must not have a history of allergic or other serious reactions to doripenem
             or any beta-lactam antibiotic, benzodiazepines or lidocaine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith A. Rodvold, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois at Chicago</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Larry H. Danziger, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois at Chicago</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark H. Gotfried, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pulmonary Associates, PA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pulmonary Associates, PA</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2009</study_first_submitted>
  <study_first_submitted_qc>June 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2009</study_first_posted>
  <last_update_submitted>March 12, 2013</last_update_submitted>
  <last_update_submitted_qc>March 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Illinois at Chicago</investigator_affiliation>
    <investigator_full_name>Keith A. Rodvold</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>doripenem</keyword>
  <keyword>epithelial lining fluid</keyword>
  <keyword>alveolar macrophages</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>Healthy adult subjects</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

